Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $151.00 at Citigroup

Nektar Therapeutics (NASDAQ:NKTR) had its target price raised by Citigroup from $123.00 to $151.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Oppenheimer reiterated an “outperform” rating and set a $140.00 price target on shares of Nektar Therapeutics in a research report on Friday, March 13th. Piper Sandler reissued an “overweight” rating and set a $105.00 price target on shares of Nektar Therapeutics in a research note on Monday, January 26th. TD Cowen assumed coverage on Nektar Therapeutics in a report on Tuesday, March 17th. They issued a “buy” rating on the stock. Finally, B. Riley Financial reaffirmed a “buy” rating and issued a $150.00 price objective (up from $105.00) on shares of Nektar Therapeutics in a research note on Monday, February 23rd. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $140.63.

Nektar Therapeutics Stock Performance

Nektar Therapeutics stock opened at $98.16 on Tuesday. The company has a market cap of $2.82 billion, a P/E ratio of -9.63 and a beta of 1.16. Nektar Therapeutics has a one year low of $7.99 and a one year high of $109.00. The business has a fifty day moving average of $74.35 and a two-hundred day moving average of $58.86.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.91. The business had revenue of $21.81 million for the quarter, compared to analysts’ expectations of $10.44 million. Nektar Therapeutics had a negative net margin of 297.07% and a negative return on equity of 380.32%. Sell-side analysts predict that Nektar Therapeutics will post -10.02 EPS for the current year.

Insiders Place Their Bets

In other Nektar Therapeutics news, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the transaction, the chief executive officer owned 75,489 shares in the company, valued at approximately $5,510,697. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

Several large investors have recently modified their holdings of NKTR. BNP Paribas Financial Markets boosted its position in shares of Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 210 shares during the last quarter. Deutsche Bank AG increased its position in Nektar Therapeutics by 0.8% during the fourth quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock worth $3,837,000 after purchasing an additional 743 shares during the last quarter. Bayforest Capital Ltd raised its stake in Nektar Therapeutics by 51.3% during the fourth quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 862 shares during the period. FNY Investment Advisers LLC raised its stake in Nektar Therapeutics by 70.6% during the third quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 1,077 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of Nektar Therapeutics by 22.0% in the 4th quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 1,299 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Nektar Therapeutics News Summary

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Positive 52‑week REZOLVE‑AA Phase 2b extension results — topline data showed increasing, clinically meaningful hair‑growth responses (29% and 31% achieving SALT ≤20 in the extension arms) and a favorable safety profile, which the company says supports late‑stage advancement. This is the main catalyst behind recent upside. 52‑Week Topline Results PR
• Positive Sentiment: Analyst price‑target upgrades and buy calls — multiple firms raised targets (examples: HC Wainwright, BTIG, Citigroup; Wedbush raised its target while keeping a neutral rating). Those lifts amplified buying interest and helped drive volume and momentum. Analyst Coverage/Price Target Moves
• Neutral Sentiment: Trading halt for “news pending” occurred ahead of the PR — a routine mechanism that briefly paused trading while results were released; it amplified intraday volatility but is not itself a directional fundamental.
• Negative Sentiment: Proposed $250M underwritten public offering — Nektar filed to sell common stock and pre‑funded warrants, which raises dilution risk and can pressure the share price even as proceeds fund development. Offering Announcement
• Negative Sentiment: Multiple securities‑class action lawsuits and law‑firm solicitations — several firms have filed or are soliciting lead plaintiffs alleging securities violations tied to a Feb‑Dec 2025 class period; legal actions increase headline risk, potential costs, and create uncertainty for shareholders. Pomerantz Filing Bronstein Notice

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.